接受承诺疗法（ACT）治疗炎症性肠病（IBD）相关心理困扰：ACTforIBD 方案的可行性试验方案。
Acceptance commitment therapy (ACT) for psychological distress associated with inflammatory bowel disease (IBD): protocol for a feasibility trial of the ACTforIBD programme.
机构信息
Psychology, Deakin University Faculty of Health, Burwood, Victoria, Australia
School of Pyschology, Deakin, Geelong, Victoria, Australia.
出版信息
BMJ Open. 2022 Jun 10;12(6):e060272. doi: 10.1136/bmjopen-2021-060272.
INTRODUCTION
Inflammatory bowel disease (IBD) involves an abnormal immune response to healthy gut bacteria. When a person develops IBD, their susceptibility to anxiety and/or depression increases. The ACTforIBD programme, specifically designed for people with IBD and comorbid psychological distress, draws on acceptance and commitment therapy (ACT), which promotes acceptance of situations that cannot be solved such as persistent physical symptoms. There are no ACT trials for IBD using an active control group or a telemedicine approach, which is important to improve accessibility, particularly in the context of the ongoing COVID-19 pandemic. The ACTforIBD programme is administered online with a 4-hour therapist involvement per participant only; if successful it can be widely implemented to improve the well-being of many individuals with IBD.
METHODS AND ANALYSIS
Our team have codesigned with consumers the ACTforIBD programme, an 8-week intervention of 1-hour sessions, with the first three sessions and the last session delivered one-to-one by a psychologist, and the other sessions self-directed online. This study aims to evaluate the feasibility and preliminary efficacy of ACTforIBD to reduce psychological distress in patients with IBD. Using a randomised controlled trial, 25 participants will be randomised to ACTforIBD, and 25 patients to an active control condition.
ETHICS AND DISSEMINATION
This protocol has been approved by Deakin University Research Ethics Committee in September 2021 (Ref. 2021-263) and the New Zealand Central Health and Disability Ethics Committee in December 2021 (Ref. 2021 EXP 11384). The results of this research will be published in peer-reviewed journals and shared with various stakeholders, including community members, policy-makers and researchers, through local and international conferences.
TRIAL REGISTRATION NUMBER
ACTRN12621001316897.
简介
炎症性肠病（IBD）涉及对健康肠道细菌的异常免疫反应。当一个人患上 IBD 时，他们患焦虑症和/或抑郁症的风险会增加。ACTforIBD 计划是专门为患有 IBD 和合并心理困扰的人设计的，它借鉴了接受与承诺疗法（ACT），该疗法促进对无法解决的情况的接受，例如持续的身体症状。目前尚无使用活性对照组或远程医疗方法的针对 IBD 的 ACT 试验，这对于提高可及性非常重要，尤其是在当前 COVID-19 大流行的背景下。ACTforIBD 计划通过在线进行管理，每位参与者仅需要治疗师 4 小时的参与；如果成功，它可以广泛实施，以改善许多 IBD 患者的幸福感。
方法和分析
我们的团队与消费者共同设计了 ACTforIBD 计划，这是一项为期 8 周、每小时一次的干预措施，其中前三节和最后一节由心理学家一对一进行，其他课程则在线自行完成。本研究旨在评估 ACTforIBD 减少 IBD 患者心理困扰的可行性和初步疗效。采用随机对照试验，将 25 名参与者随机分配至 ACTforIBD 组，25 名患者分配至活性对照组。
伦理和传播
该方案已于 2021 年 9 月获得迪肯大学研究伦理委员会的批准（Ref. 2021-263）和 2021 年 12 月新西兰中央卫生和残疾伦理委员会的批准（Ref. 2021 EXP 11384）。这项研究的结果将发表在同行评议的期刊上，并通过当地和国际会议与社区成员、政策制定者和研究人员等各种利益相关者分享。
试验注册号
ACTRN12621001316897。
Zotero 插件